DAFNA Capital Management’s Immunovant IMVT Stock Holding History

DAFNA Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.76M	Sell	149,524 -1,000	-0.7%	-$30.5K	1.1%	24
2026 Q1	$3.74M	Hold	150,524	–	–	0.85%	32
2025 Q4	$3.83M	Sell	150,524 -40,969	-21%	-$914K	0.89%	28
2025 Q3	$3.09M	Hold	191,493	–	–	0.76%	35
2025 Q2	$3.06M	Buy	191,493 +21,497	+13%	+$325K	0.85%	30
2025 Q1	$2.91M	Buy	169,996 +62,000	+57%	+$1.3M	0.82%	32
2024 Q4	$2.68M	Buy	107,996 +56,000	+108%	+$1.59M	0.68%	32
2024 Q3	$1.48M	Buy	51,996 +4,080	+9%	+$120K	0.35%	55
2024 Q2	$1.26M	Buy	47,916 +18,500	+63%	+$526K	0.3%	57
2024 Q1	$950K	Sell	29,416 -11,326	-28%	-$413K	0.22%	60
2023 Q4	$1.72M	Buy	40,742 +18,242	+81%	+$671K	0.41%	46
2023 Q3	$864K	Buy	+22,500	New	+$509K	0.27%	61

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DAFNA Capital Management's IMVT Position: Q2 2026 in Review

DAFNA Capital Management reduced its Immunovant (IMVT) stake by 0.66% in Q2 2026, selling an estimated $30.5K and leaving 149,524 shares worth $5.76M. The position accounts for 1.1% of the portfolio, ranked #24.

DAFNA Capital Management first reported a position in IMVT in Q3 2023 and has held it in 12 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

DAFNA Capital Management held 149,524 shares of Immunovant worth $5.76M as of Q2 2026.
DAFNA Capital Management sold 1,000 Immunovant shares in Q2 2026, an estimated $30.5K.
Immunovant made up 1.1% of DAFNA Capital Management's portfolio in Q2 2026, its #24 holding.
DAFNA Capital Management first reported a position in Immunovant in Q3 2023 and has held it in 12 quarters since.
226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.